Blog
RSS FeedPosted by Michael Wonder on 29 Mar 2022
Government fails to adequately address medicine affordability for working Australians
29 March 2022 - The cost of medicines will continue to go up unchecked as the Federal Government has failed ...
Posted by Michael Wonder on 28 Mar 2022
Federal Budget vision must extend beyond election day to secure better long-term health for all Australians
28 March 2022 - Medicines Australia is hoping tomorrow’s Budget reveals a long-term vision for health with strong investments in ...
Posted by Michael Wonder on 26 Mar 2022
Landmark PBS listing for Australians with cystic fibrosis
27 March 2022 - From April 1 2022, Trikafta (elexacaftor with tezacaftor and ivacaftor and ivacaftor) will be available on ...
Posted by Michael Wonder on 25 Mar 2022
Expanded PBS listing for lung disease medication
25 March 2022 - The Australian Government is helping more Australians access the medications they need with a new addition to ...
Posted by Michael Wonder on 21 Mar 2022
Mum’s fear as promising cancer drug out of reach
21 March 2022 - A terminally ill mum desperate for “more time” with her family was “broken” when she learnt the ...
Posted by Michael Wonder on 15 Mar 2022
Better care and treatment for Australians with blood cancer
15 March 2022 - Australians with blood cancer will receive improved treatment and care through new and continued funding from the ...
Posted by Michael Wonder on 02 Mar 2022
BeiGene hits major milestone with first PBS approved cancer treatment
1 March 2022 - BeiGene is welcoming the listing of Brukinsa (zanubrutinib), a targeted treatment for mantle cell lymphoma, an aggressive ...
Posted by Michael Wonder on 01 Mar 2022
New PBS listings from 1 March 2022
1 March 2022 - Australians will have access to four new medicines through the Pharmaceutical Benefits Scheme from March 1 to ...
Posted by Michael Wonder on 28 Feb 2022
Lagevrio (molnupiravir) PBS listing
1 March 2022 - Commencing 1 March 2022, Lagevrio (molnupiravir) will be listed on the PBS Section 85 program as an ...
Posted by Michael Wonder on 28 Feb 2022
Schedule of Pharmaceutical Benefits - 1 March 2022
1 March 2022 - The March 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 26 Feb 2022
Landmark PBS listing for Australians with leukaemia
25 February 2022 - From 1 March 2022, Australians with acute myeloid leukaemia will have access to a new treatment option ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 21 Feb 2022
PBS arrangements for medicines for the treatment of paroxysmal nocturnal haemoglobinuria
21 February 2022 - Commencing 1 March 2022, Soliris (eculizumab) and Ultomiris (ravulizumab) will be listed on the Pharmaceutical Benefits Scheme ...
Posted by Michael Wonder on 20 Feb 2022
New PBS listing to help fight chronic graft versus host disease
20 February 2022 - From 1 March 2022, Australians with chronic graft versus host disease, a complication that can occur when ...